Zuber Lawler Opens New Office in Austin
March 9, 2021 | Press
Zuber Lawler gratefully announces the addition of Austin-based intellectual property litigator Jennifer Kuhn, and the opening of its new office in Austin, Texas. “Austin is the new technology capital of the United States, and as a technology-focused law firm, my partners and I have decided that we must have an office there,” says the firm’s Managing Partner Tom Zuber. “Ms. Kuhn is an impeccably pedigreed and highly accomplished intellectual property litigator, and an esteemed leader within the Texas legal community. We’re thrilled that she has decided to join Zuber Lawler.”
Jennifer Kuhn focuses on patent litigation, technology transfer, data protection and privacy matters. She also has experience with trademark, copyright, and trade secret matters.
Prior to joining Zuber Lawler, Ms. Kuhn practiced at AmLaw 100 firms in Washington, D.C., Silicon Valley, and Austin, before becoming Vice President and Chief IP Counsel at Mattersight Corporation (NASDAQ MATR), where she managed the company’s IP litigation and patent portfolio. Mattersight was named one of the “Top 5 IP Innovators” by Crain’s Chicago Business, and Ms. Kuhn is a named inventor on four Mattersight patents: U.S. Patent Nos. 9,300,801, 9,538,008, 9,942,590 and 10,276,153.
Ms. Kuhn started her career as a judicial clerk first to the Honorable Andewalt of the United States Court of Federal Claims; and then to the Honorable Judge Gajarsa of the United States Court of Appeals for the Federal Circuit.
Ms. Kuhn’s amicus briefs have been cited by the Federal Circuit (Lightning Ballast) and followed by the U.S. Supreme Court (Bilski).
Ms. Kuhn coached the IP Moot Court team at the University of Texas School of Law to four National Championships.
Jennifer earned her J.D. cum laude at Cornell Law School, where she was a member of the Law Review.
She is admitted in Texas.
Recent Updates
An FDA Panel Just Voted to Widen Access to Peptides. Here’s What It Actually Means for the Longevity Space July 30, 2026
Generative AI Legal Issues: 5 Critical Questions Every Business Must Answer Before Deploying AI Solutions May 21, 2026
Medical Rescheduling, Recreational Risk: How Schedule III Could Reshape Adult-Use Cannabis February 18, 2026
Schedule III Cannabis: FDA’s New Frontier January 27, 2026
Data Privacy and AI in Longevity: Legal Risks Around Predictive Biomarkers and Health Data January 23, 2026
2026 Employment Law Developments: Key Takeaways for Employers December 22, 2025